Australia Markets closed

AVXL Jan 2023 13.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
8.74+0.12 (+1.39%)
At close: 03:47PM EDT
Full screen
Previous close8.62
Open8.74
Bid6.50
Ask10.40
Strike13.00
Expiry date2023-01-20
Day's range8.74 - 8.74
Contract rangeN/A
Volume10
Open interest15
  • GlobeNewswire

    Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

    NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H

  • GlobeNewswire

    Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

    Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter end

  • GlobeNewswire

    Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

    Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ETNEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial r